Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-strauss ... The most common symptoms and signs include extreme fatigue, weight loss, muscle and joint pain, rashes, nerve ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...
Biopsies from the lower limb rash showed a perivascular lymphocytic infiltrate ... Whipple’s disease, rheumatoid arthritis, granulomatosis with polyangiitis, Behçet’s syndrome, inflammatory bowel ...
Children with antineutrophil cytoplasmic antibody–associated vasculitis had similar remissions rates with rituximab and ...
3 1. Furuta S, et al. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68:430-436. 2. American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with ...
GlobalData on MSN14d
EC approves AstraZeneca’s Fasenra for EGPA treatmentFasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic ...
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids LONDON, UK I October 28, 2024 I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback